Skip to main content
SpringerLink
Log in

Molecular and Physiologic Mechanisms of Drug Resistance in Cancer: An Overview

  • Editorial Introduction
  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Druker BJ,Talpaz M,Resta DJ,Peng B,Buchdunger E,Ford JM,Lydon NB,Kantarjian H,Capdeville R,Ohno-Jones S,Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037, 2001

    Google Scholar 

  2. Druker BJ,Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3–7, 2000

    Google Scholar 

  3. Blanke CD,von Mehren M,Joensuu H,Roberts PJ,Eisenberg B,Heinrich M,Druker B,Tuveson D,Dimitrijevic S,Siberman SL,Demetri GD: Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing C-KIT (CD17). Proc. Am. Soc. Clin. Oncol. 1a 2001 ( abstract)

  4. van Oosterman AT,Judson I,Verwej J,Paola ED,van Glabbeke M,Dimitrijevic S,Nelsen O: STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study. Proc. Am. Soc. Clin. Oncol., 2a 2001 ( abstract)

  5. Joensuu H,Roberts PJ,Sarlomo-Rikala M,Andersson LC,Tervahartiala P,Tuveson D,Silberman S,Capdeville R,Dimitrijevic S,Druker B,Demetri GD: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052–1056, 2001

    Google Scholar 

  6. Helmlinger G,Yuan F,Dellian M,Jain RK: Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177–182, 1997

    Google Scholar 

  7. Druker BJ,Sawyers CL,Kantarjian H,Resta DJ,Reese SF,Ford JM,Capdeville R,Talpaz M: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042, 2001

    Google Scholar 

  8. Gorre ME,Mohammed M,Ellwood K,Hsu N,Paquette R,Rao PN,Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 21: 2001

  9. Marx J: Cancer research. Why some leukemia cells resist STI-571. Science 292: 2231–2233, 2001

    Google Scholar 

  10. Viloria-Petit A,Crombet T,Jothy S,Rak J,Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61: 5090–5101, 2001

    Google Scholar 

  11. Gambacorti-Passerini C,Barni R,le Coutre P,Zucchetti M,Cabrita G,Cleris L,Rossi F,Gianazza E,Brueggen J,Cozens R,Pioltelli P,Pogliani E,Corneo G,Formelli F,D'Incalci M: Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92: 1641–1650, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cancer Biology Research, Sunnybrook Health Science Centre, Toronto, Ontario, Canada

    R.S. Kerbel

Authors
  1. R.S. Kerbel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerbel, R. Molecular and Physiologic Mechanisms of Drug Resistance in Cancer: An Overview. Cancer Metastasis Rev 20, 1–2 (2001). https://doi.org/10.1023/A:1013129128673

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013129128673

Search

Navigation